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Abstract 
It has been demonstrated that microRNAs (miRNAs or miRs) can act as prognostic and diagnostic markers, and 
potential therapeutic targets. miR-95-3p has been reported to be downregulated in osteosarcoma tissues, but its 
potential as a serum biomarker has not been assessed in human osteosarcoma. The purpose of the present study 
was to examine the expression levels of miR-95-3p in serum of patients with osteosarcoma and to investigate the 
diagnostic and prognostic value of miR-95-3p. The serum levels of miR-95-3p in osteosarcoma patients were detected 
by a real-time quantitative reverse transcription-polymerase chain reaction assay. Associations between miR-95-3p 
expression and various clinicopathological characteristics were analyzed using Chi square test. Differences in patient 
survival were determined using the Kaplan–Meier method and a log-rank test. A Cox proportional hazards regression 
analysis was used for multivariate analyses of prognostic values. Compared to healthy controls, the expression levels 
of miR-95-3p in serum of osteosarcoma patients were significantly decreased (P < 0.0001). Low miR-95-3p expression 
had significant association with clinical stage (P < 0.001) and metastasis (P < 0.001). The Kaplan–Meier curve showed 
that patients with high miR-95-3p expression survived significantly longer than patients with low miR-95-3p expres-
sion (P = 0.017). Multivariate analysis demonstrated that miR-95-3p expression level (P = 0.014) was an independent 
prognostic biomarker for overall survival. Our findings suggested that down-expression of serum miR-95-3p might be 
associated with poor prognosis of osteosarcoma patients, suggesting that decreased expression of serum miR-95-3p 
may serve as a valuable diagnostic/prognostic marker for osteosarcoma patients.
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Background
Osteosarcomas are aggressive neoplasms of the bone that 
occurs predominantly in adolescents and young adults. 
Due to the low incidence of osteosarcomas and strong 
heterogeneous nature of osteosarcoma, the molecular 
pathogenesis of osteosarcoma is not well understood 
compared to other cancer types. The 5-year overall and 
disease-free survival rates for osteosarcoma patients are 
approximately 50–60%, and about 40% of patients died 
from lung metastases (Bruland et  al. 2010). In recent 
years, neoadjuvant chemotherapy with cisplatin, doxoru-
bicin, ifosfamide and methotrexate has been widely used 
to reduce the recurrence rates and improve the survival 
of patients with osteosarcoma. Resistance to chemother-
apeutic agents is still the main problem in osteosarcoma 
and cancer treatment. Detection of cancer biomark-
ers in human serum is a novel method in diagnosis and 
prognosis of cancer. In clinical practice, levels of serum 
lactate dehydrogenase (LDH) are routinely measured in 
the diagnosis of myocardial infarction, liver disease and 
certain malignancies because it is released during tissue 
damage. Elevated serum LDH were found to correlate 
with a larger tumor burden and to predict a poor progno-
sis (Miao et al. 2013). Alkaline phosphatase (ALP) plays 
an important role in osteoarticular processes. The serum 
level of bone-specific ALP reflects the cellular activity of 
osteoblasts, and elevated serum level of ALP has been 
found during bone formation or increased bone turno-
ver (Pääkkönen et  al. 2013). However, there is still no 
effective serum indicator for diagnosis and prognosis of 
patients with osteosarcoma.
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micro-RNA (miRNA or miR), a highly conserved non-
coding RNA molecule with 18–25 nucleotides, regulates 
gene expression at the post-transcriptional level by bind-
ing to the 3′-untranslated regions of their target mRNAs 
(Ha and Kim 2014). miRNAs can control as many as 60% 
of protein coding genes in human (Namløs et  al. 2012). 
miRNAs involve in multiple cellular processes, such as 
differentiation, proliferation, and apoptosis, which are 
of great importance in the development of cancer (Jones 
et al. 2012). With the development of biotechnologies for 
miRNA expression profiling, an increasing number of 
studies have suggested that miRNAs may be closely asso-
ciated with initiation and progression of cancer. More 
than half of the annotated miRNAs were found to be 
located within fragile sites of human genome that were 
related to cancer (Huang et  al. 2013). The level of miR-
95-3p was upregulated in higher-grade glioma tissues of 
patients with glioma. In glioma cells, downregulation of 
miR-95-3p inhibits proliferation, invasion and promotes 
apoptosis (Fan et al. 2015). In mice, experiments showed 
that miR-95-3p overexpression promoted tumor growth 
and increased radiation resistance in tumor xenografts 
(Huang et al. 2013). Lawrie et al. (2008) found that high 
levels of miR-155a and miR-210 in serum were correlated 
with disease-free survival rates of patients with diffuse 
large B cell lymphoma. As oncogenes or tumor suppres-
sors, circulating miRNAs may develop to be a promising 
diagnostic and prognostic marker for various types of 
cancer, including osteosarcoma, nasopharyngeal carci-
noma, glioma, as well as breast, gastric, prostate and lung 
cancer.
There are many advantages for circulating miRNAs in 
serum to be promising biomarkers. First, Serum samples 
are more easily accessible compared with tumor tissue 
samples. Second, due to protection of serum, miRNAs 
are highly resistant to RNase-mediated degradation and 
other severe conditions such as extreme pH, high tem-
perature, and repeated freeze–thaw cycles. Third, most 
of miRNAs are evolutionarily conserved in animal, plant 
and bacterial viruses. Finally, sufficient miRNAs in serum 
make it easy to be determined by simple and fast meth-
ods (Etheridge et  al. 2011; Lodes et  al. 2009; Ma et  al. 
2012; Park et al. 2009).
In the present study, we detected the expression levels 
of miR-95-3p in serum samples of osteosarcoma patients 
and healthy individuals. Then, the correlations between 
serum miR-95-3p level and clinicopathological factors 
or overall survival of osteosarcoma patients were evalu-
ated. The prognostic value of miR-95-3p expression level 




The experiments was approved by the Ethics Review 
Board of Zhengzhou Orthopedics Hospital. Tumor 
tissues and matched serum samples were collected 
after obtaining written informed consents from each 
participant.
In total, 133 patients diagnosed with osteosarcoma 
(Fig. 1) and 133 sex- and age-matched healthy individuals 
from Zhengzhou Orthopedics Hospital between March 
2013 and July 2015 were recruited in this study. Neither 
chemotherapy nor radiotherapy had been used in all of 
the patients before surgery treatment. Clinical informa-
tion of patients was obtained from medical records and 
pathology reports. Tumor stage was classified accord-
ing to the tumor-lymph node-metastasis classification 
system of the International Union against Cancer. All of 
the osteosarcoma patients received regular followed-up. 
Fig. 1 The imaging features of osteosarcoma. a MRI findings included osteolytic destruction, joint effusion and soft tissue mass. b, c X-ray showed 
osteolytic bone destruction in proximal tibia. d, e Histological data showed fusiform osteosarcoma cells
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Overall survival time was defined as the time interval 
from primary surgery to the date of death or last follow-
up. The clinicopathological data of patients was retro-
spectively reviewed and summarized in Table 1.
For each subject, 3  mL venous blood was collected 
from 133 patients and placed in a test tube. The whole 
blood samples were incubated at 37 °C for 1 h and then 
centrifuged immediately at 1500g for 15 min at 4 °C. The 
serum was stored in 1.5 mL RNase free tubes at −80 °C 
for RNA extraction.
RNA isolation
Total RNA was isolated from fresh osteosarcoma tis-
sue and serum samples using the miRNeasy Mini Kit 
(Qiagen, Valencia, CA, USA) and miRVana RNA isola-
tion kit (Ambion Inc, Austin TX, USA) according to the 
manufacturer’s protocol. RNA purity and concentra-
tions were measured with the Nanodrop 2000 (Thermo 
Fisher Scientific, San Jose, CA, USA). RNA integrity was 
detected on a agarose gel with ethidium bromide staining 
by electrophoresis. The RNA samples were immediately 
stored at −80 °C for next cDNA convertion.
qRT‑PCR
cDNA was synthesized by reverse transcription reac-
tion using the TaqMan miRNA Reverse Transcrip-
tion Kit (Applied Biosystems, Foster City, CA, USA) 
according to the manufacturer’s protocol. 100 ng tissue-
derived RNA or 40 ng serum-derived RNA was used in 
the reverse transcription reactions. The expression level 
of precursor miR-95 was quantified using SYBR green 
qRT-PCR assay (Invitrogen, Carlsbad, CA, USA) and 
real-time PCR was performed on a MyiQ Real-Time 
PCR Detection System (Bio-Rad, Richmond, CA, USA). 
The nuclear RNA U6 was used as an endogenous con-
trol for the expression of precursor miR-95. Each sample 
was examined in triplicate in 20 μL volumes, including 
no-template controls. The following primers (Sangon 
Biotech, Shanghai, China) were used: precursor miR-
95 forward, 5′-CTGGTGGAGGGATGGATGAA-3′; 
reverse, 5′-GGCCCGATCACAAACTCATC-3′; U6 for-
ward, 5′-AACGCTTCACGAATTTGCGT-3′; reverse, 
5′-CTCGCTTCGGCAGCACA-3′. The 2−ΔΔCt cycle 
threshold method was used to qualify the relative expres-
sion level of miR-95-3p.
Statistical analysis
Continuous variables were expressed as mean ±  stand-
ard deviation (SD). Associations between serum levels 
of miR-95-3p and clinicopathological characteristics or 
survival of osteosarcoma patients were evaluated using 
Chi square test. Survival rate was determined using the 
Kaplan–Meier method and differences between groups 
were examined using Log-rank test. Survival data were 
assessed by multivariate Cox regression analysis. All P 
values were two-sided and P < 0.05 was considered sta-
tistically significant. The statistical analyses of all experi-
mental data were conducted using SPSS 18.0 statistical 
software (SPSS Inc., Chicago, IL, USA).
Results
Decreased levels of serum miR‑95‑3p in osteosarcoma 
patients
qRT-PCR was conducted to determine the expression 
levels of serum miR-95-3p in patients with osteosarcoma 
and sex- and age-matched healthy controls. miR-95-3p 
expression levels were significantly decreased in serum of 









 ≤15 59 40 19 0.234
 >15 74 57 17
Sex
 Male 71 53 18 0.634
 Female 62 44 18
Location
 Tibia 58 44 14 0.375
 Femur 31 25 6
 Splinter bone 22 16 6
 Humeral bone 15 12 3
 Elsewhere 7 5 2
Tumor diameter (cm)
 ≤5 73 52 21 0.627
 >5 60 45 15
Serum level of lactate dehydrogenase
 Elevated 72 50 22 0.325
 Normal 61 47 14
Serum level of alkaline phosphatase
 Elevated 87 64 23 0.822
 Normal 46 33 13
Clinical stage
 IIA 49 27 22 0.000
 IIB/III 84 70 14
Metastasis
 Yes 68 40 28 0.000
 No 65 57 8
Response to chemotherapy
 Good 57 32 25 0.000
 Poor 76 65 11
Page 4 of 6Niu et al. SpringerPlus  (2016) 5:1947 
patients with osteosarcoma in comparison with those of 
healthy controls (mean ± SD 0.78 ± 0.32 vs. 1.01 ± 0.42, 
P < 0.0001, Fig. 2).
Association between decreased serum levels of miR‑95‑3p 
expression and clinicopathologic characteristics 
in osteosarcoma patients
We divided the patients into two groups using the 
median value of serum miR-95-3p expression levels in 
osteosarcoma patients as a cutoff point (0.75). Of 133 
osteosarcoma specimens, 69 osteosarcoma specimens 
(51.87%) showed low expression of miR-95-3p. To fur-
ther investigate the roles of miR-95-3p in the develop-
ment and progression of osteosarcoma, the association 
between miR-95-3p expression and clinicopathologi-
cal features of patients with osteosarcoma was analyzed 
using Chi square test. As shown in Table 1, low-expressed 
miR-95-3p showed significant association with clinical 
stage (P =  0.000), metastasis (P =  0.000), and response 
to chemotherapy (P = 0.000). In contrast, no significant 
association was found between the expression level of 
miR-95-3p with patients’ age (P = 0.234), sex (P = 0.634), 
location (P  =  0.375), and tumor diameter (P  =  0.627). 
Taken together, these results demonstrated that low miR-
95-3p expression in serum was associated with the pro-
gression and development of osteosarcoma.
Decreased expression of miR‑95‑3p in serum associates 
with poor prognosis in osteosarcoma patients
The correlation between miR-95-3p expression level, 
overall survival (Fig. 3a, P = 0.017) and disease-free sur-
vival (Fig.  3b, P =  0.008) of the patients with osteosar-
coma was assessed using Kaplan–Meier survival analysis. 
The Kaplan–Meier curves for overall survival showed 
that osteosarcoma patients with high miR-95-3p expres-
sion in serum survived significantly longer than those 
Fig. 2 Diagnostic value of serum miR-95-3p expression for osteosarcoma patients. a Serum miR-95-3p expression levels in 133 osteosarcoma 
patients and 133 sex- and age-matched healthy controls were determined by qRT-PCR. The serum levels of miR-95-3p were significantly decreased 
in osteosarcoma patients in comparison with healthy controls. b ROC curve analysis showed that serum miR-95-3p was a novel potential biomarker 
for early diagnosis of osteosarcoma (AUC = 0.863)
Fig. 3 Kaplan-Meier survival curves for osteosarcoma patients with high or low expression of miR-95-3p. The overall survival curves and disease-
free survival curves for two groups of osteosarcoma patients with low and high expression of serum miR-95-3p. a The overall survival rate of 
osteosarcoma patients with high miR-95-3p expression were significantly higher than those with low miR-95-3p expression (P = 0.017). b The 
disease-free survival rate of osteosarcoma patients with high miR-95-3p expression were significantly higher than those with low miR-95-3p expres-
sion (P = 0.008)
Page 5 of 6Niu et al. SpringerPlus  (2016) 5:1947 
with low miR-95-3p expression (log-rank test, P = 0.017, 
shown in Fig. 3a). Multivariate Cox proportional hazards 
model analysis suggested that expression level of serum 
miR-95-3p was a significant independent prognostic fac-
tor of overall survival for patients with osteosarcoma (HR 
4.22, 95% CI 2.314–8.072, P = 0.014, shown in Table 2).
Discussion
miRNAs play crucial roles in multiple cellular processes 
and are associated with development and progression of 
various cancers and diseases. Several circulating miRNAs 
were identified as promising biomarkers and provided 
guidance for early detection and blood screening for 
occult malignancy, including glioma (Wang et al. 2012), 
breast (Ng et al. 2013, Schrauder et al. 2012), lung (Yan 
et al. 2015), prostate (Sita-Lumsden et al. 2013), and colo-
rectal cancer (Menéndez et  al. 2013). The finding that 
serum miRNAs act as potential biomarkers for cancer 
overcomes the disadvantages of collecting tissue sam-
ples from patients through biopsy or surgery. Recently, 
A growing body of studies have showed that aberrant 
expression of miRNAs is associated with prognosis and 
progression in human osteosarcoma (Azam et  al. 2015; 
Kobayashi et al. 2014; Ouyang et al. 2013).
miR-95-3p were downregulated in both high and low 
grade osteosarcoma tissues compared with normal con-
trols (Novello et  al. 2013). Hwang et  al. (2015) revealed 
that overexpression of microRNA-95-3p inhibited brain 
metastasis of lung adenocarcinoma through downregu-
lation of cyclin D1. Their data suggested that targeting 
miR-95-3p may be a novel therapeutic strategy for brain 
metastasis of lung adenocarcinoma cells. However, the 
potential roles of miR-95-3p in pathogenesis and progno-
sis of osteosarcoma are not yet illustrated. In this study, 
the expression levels of miR-95-3p in serum were deter-
mined in osteosarcoma patients and healthy controls. The 
diagnostic value of serum miR-95-3p expression for oste-
osarcoma patients was assessed. Our data showed that 
miR-95-3p could distinguish osteosarcoma patients from 
healthy controls efficiently (AUC  =  0.863). The AUC 
value is an indicator of efficacy of the assessment system. 
In addition, we found that downregulation of serum miR-
95-3p in osteosarcoma patients was significantly associ-
ated with unfavorable clinicopathological characteristics, 
including metastasis, clinical stage and chemotherapy 
resistance. These findings suggested that a lower expres-
sion level of serum miR-95-3p was implicated in the 
pathogenesis and progression of osteosarcoma. Further-
more, Kaplan–Meier analysis and log-rank test for over-
all survival showed that patients with low serum level of 
miR-95-3p had remarkably shorter overall survival time 
than those with high expression of serum miR-95-3p. The 
multivariate Cox proportional hazards model suggested 
that clinical stage, metastasis, and decreased expression 
of serum miR-95-3p were detected to be as independent 
prognostic factors for overall survival.
We firstly demonstrated that decreased serum level of 
miR-95-3p may act as a diagnostic and prognostic bio-
marker for patients with osteosarcoma. Nevertheless, 
miRNA expression is regulated by genetic and epigenetic 
factors in human and there are some possible causes for 
the dysregulation of miRNA in various malignancy. For 
example, MYC and MYCN genes regulate the expres-
sion of miR-9 in breast cancer, and DNA methylation 
influences miR-9 expression in colorectal cancer (Vinci 
et  al. 2013). The expression of miR-95-3p was elevated 
in colorectal carcinoma, Hela cells and pancreatic car-
cinoma, which suggested that miR-95-3p may play an 
oncogenic role in these carcinomas (Huang et al. 2011). 
In the present study, we demonstrated that miR-95-3p 
worked as an anti-oncogenic miRNA in osteosarcoma 
and decreased expression of miR-95-3p was a statistically 
significant risk factor reducing overall survival in osteo-
sarcoma patients. However, the molecular mechanism of 
miR-95-3p in osteosarcoma tumorigenesis and progres-
sion has not yet been elucidated.
Conclusion
Our results suggested that miR-95-3p expression may 
decreased in serum of osteosarcoma patients. Detection 
of serum miR-95-3p levels may have clinical potentials 
as a valuable diagnostic and prognostic biomarker for 
osteosarcoma patients. Further studies should be con-
ducted to clarify the exact mechanism of miR-95-3p in 
osteosarcoma.
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